Abstract
The present study aimed at establishing the CD50 and CD99 doses along with complete dose-response profile of two convulsants, namely, kainic acid and pentylenetetrazole (PTZ), in mice and evaluating the modulatory role of the cerebroselective dihydropyridine calcium channel blocker nimodipine. Kainic acid and PTZ were administered intraperitoneally in a dose range of 1-30 mg kg(-1) and 35-75 mg kg(-1), respectively. Nimodipine was administered in graded doses (1-8 mg kg(-1), i.p.) with 15 min pretreatment time against CD99 doses of both kainic acid and PTZ. The effect of nimodipine in treated groups was compared with that of vehicle in control group. The CD50 and CD99 doses for kainic acid was found to be 2.5 and 7.5 mg kg(-1), while those of PTZ were found to be 50 and 75 mg kg(-1), respectively. Pretreatment with nimodipine inhibited seizures in a dose-dependent manner, in terms of both percentage of positive responders and seizure scores against CD99 doses of both kainic acid and PTZ. The results established the protective efficacy of nimodipine against both kainic acid and PTZ-induced seizures, suggesting the role of calcium ion as a common mediator for both the types of seizures. However, further studies are necessary to ascertain the exact molecular mechanism of nimodipine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Methods and Findings in Experimental and Clinical Pharmacology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
